Investors & Media

In the News

In the News

Anokion scientists showcase tolerance technology in immunogenicity reduction of therapeutics

Anokion scientists showcase tolerance technology in immunogenicity reduction of therapeutics

Anokion scientists have successfully applied the company’s proprietary erythrocyte-binding technology to induce humoral immune tolerance towards a highly foreign therapeutic drug in a pre-clinical setting. Asparaginase, an E. coli enzyme used to treat acute lymphoblastic leukemia, was engineered for erythrocyte binding and was demonstrated to reduce anti-drug antibody responses over 1,000-fold in mice. Additionally, the engineered asparaginase induced lasting immune tolerance which enabled follow-on treatment with the wild-type drug. The results were recently published in the peer-reviewed journal Science Advances (full article here).

View All